Relationship between CT characteristics and human epidermal growth factor receptor 2 expression in gastric cancers

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108. https://doi.org/10.3322/caac.21262.

Jim MA, Pinheiro PS, Carreira H, Espey DK, Wiggins CL, Weir HK. Stomach cancer survival in the United States by race and stage (2001–2009): findings from the CONCORD-2 study. Cancer. 2017;123(Suppl 24):4994–5013. https://doi.org/10.1002/cncr.30881.

Moasser MM. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene. 2007;26(45):6469–87. https://doi.org/10.1038/sj.onc.1210477.

Cordts Filho RM, Kassab P, Claro LC, Fracassi MT, Colombo-Souza P, Fukuhara DK, et al. Evaluation of the expression of the human epithelial receptor 2 (HER2) in gastric carcinoma. Sci World J. 2016;2016:7951365. https://doi.org/10.1155/2016/7951365.

Maximiano S, Magalhaes P, Guerreiro MP, Morgado M. Trastuzumab in the treatment of breast cancer. BioDrugs Clin Immunother Biopharm Gene Ther. 2016;30(2):75–86. https://doi.org/10.1007/s40259-016-0162-9.

Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, de Azambuja E, et al. 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet. 2017;389(10075):1195–205. https://doi.org/10.1016/S0140-6736(16)32616-2.

Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–97. https://doi.org/10.1016/S0140-6736(10)61121-X.

Chen R, Zhou X, Liu J, Huang G. Relationship between 18F-FDG PET/CT findings and HER2 expression in gastric cancer. J Nucl Med. 2016;57(7):1040–4. https://doi.org/10.2967/jnumed.115.171165.

He J, Shi H, Zhou Z, Chen J, Guan W, Wang H, et al. Correlation between apparent diffusion coefficients and HER2 status in gastric cancers: pilot study. BMC Cancer. 2015;15:749. https://doi.org/10.1186/s12885-015-1726-7.

Hofmann M, Stoss O, Shi D, Buttner R, van de Vijver M, Kim W, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology. 2008;52(7):797–805. https://doi.org/10.1111/j.1365-2559.2008.03028.x.

Ahn HS, Kim SH, Kodera Y, Yang HK. Gastric cancer staging with radiologic imaging modalities and UICC staging system. Digestive Surg. 2013;30(2):142–9. https://doi.org/10.1159/000350881.

Park HS, Lee JM, Kim SH, Lee JY, Yang HK, Han JK, et al. Three-dimensional MDCT for preoperative local staging of gastric cancer using gas and water distention methods: a retrospective cohort study. AJR Am J Roentgenol. 2010;195(6):1316–23. https://doi.org/10.2214/AJR.10.4320.

Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17(6):1471–4. https://doi.org/10.1245/s10434-010-0985-4.

Badescu A, Georgescu CV, Vere CC, Craitoiu S, Grigore D. Correlations between Her2 oncoprotein, VEGF expression, MVD and clinicopathological parameters in gastric cancer. Romanian J Morphol Embryol Revue Roumaine de Morphologie et Embryologie. 2012;53(4):997–1005.

Schoppmann SF, Tamandl D, Roberts L, Jomrich G, Schoppmann A, Zwrtek R, et al. HER2/neu expression correlates with vascular endothelial growth factor-C and lymphangiogenesis in lymph node-positive breast cancer. Ann Oncol. 2010;21(5):955–60. https://doi.org/10.1093/annonc/mdp532.

Kim KC, Koh YW, Chang HM, Kim TH, Yook JH, Kim BS, et al. Evaluation of HER2 protein expression in gastric carcinomas: comparative analysis of 1,414 cases of whole-tissue sections and 595 cases of tissue microarrays. Ann Surg Oncol. 2011;18(10):2833–40. https://doi.org/10.1245/s10434-011-1695-2.

He XX, Ding L, Lin Y, Shu M, Wen JM, Xue L. Protein expression of HER2, 3, 4 in gastric cancer: correlation with clinical features and survival. J Clin Pathol. 2015;68(5):374–80. https://doi.org/10.1136/jclinpath-2014-202657.

Fisher SB, Fisher KE, Squires MH 3rd, Patel SH, Kooby DA, El-Rayes BF, et al. HER2 in resected gastric cancer: is there prognostic value? J Surg Oncol. 2014;109(2):61–6. https://doi.org/10.1002/jso.23456.

He C, Bian XY, Ni XZ, Shen DP, Shen YY, Liu H, et al. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer. World J Gastroenterol. 2013;19(14):2171–8. https://doi.org/10.3748/wjg.v19.i14.2171.

Ikoma N, Blum M, Chiang YJ, Estrella JS, Roy-Chowdhuri S, Fournier K, et al. Survival rates in T1 and T2 gastric cancer: a western report. J Surg Oncol. 2016;114(5):602–6. https://doi.org/10.1002/jso.24382.

Kataoka Y, Okabe H, Yoshizawa A, Minamiguchi S, Yoshimura K, Haga H, et al. HER2 expression and its clinicopathological features in resectable gastric cancer. Gastric Cancer. 2013;16(1):84–93. https://doi.org/10.1007/s10120-012-0150-9.

Lee JS, Kim SH, Im SA, Kim MA, Han JK. Human epidermal growth factor receptor 2 expression in unresectable gastric cancers: relationship with CT characteristics. Korean J Radiol. 2017;18(5):809–20. https://doi.org/10.3348/kjr.2017.18.5.809.

Shi HZ, Wang YN, Huang XH, Zhang KC, Xi HQ, Cui JX, et al. Serum HER2 as a predictive biomarker for tissue HER2 status and prognosis in patients with gastric cancer. World J Gastroenterol. 2017;23(10):1836–42. https://doi.org/10.3748/wjg.v23.i10.1836.

Zhang XL, Yang YS, Xu DP, Qu JH, Guo MZ, Gong Y, et al. Comparative study on overexpression of HER2/neu and HER3 in gastric cancer. World J Surg. 2009;33(10):2112–8. https://doi.org/10.1007/s00268-009-0142-z.